# OnCo record ascentage-pharma (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/ascentage-pharma/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "ascentage-pharma" ;
  schema:name "Ascentage Pharma"@en ;
  schema:alternateName "Ascentage Pharma Group Inc."@en, "亚盛医药"@en ;
  schema:description "Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax."@en ;
  schema:url <https://onco.cc/companies/ascentage-pharma/>, <https://www.ascentage.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.ascentage.com>, <https://clinicaltrials.gov/search?lead=Ascentage%20Pharma>, <https://en.wikipedia.org/wiki/Ascentage_Pharma> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/aml/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/>, <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/olverembatinib/> ;
  onco:companies <https://onco.cc/companies/takeda/> ;
  onco:trials <https://onco.cc/trials/nct04501120/>, <https://onco.cc/trials/nct03611868/>, <https://onco.cc/trials/nct05701306/>, <https://onco.cc/trials/nct04785196/>, <https://onco.cc/trials/nct04494503/>, <https://onco.cc/trials/nct04496349/>, <https://onco.cc/trials/nct06389292/>, <https://onco.cc/trials/nct05147467/> .